Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab-based regimens.

MLA

De Novellis, Danilo, et al. “Cytomegalovirus Reactivation Is Frequent in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens.” Cancer Medicine, vol. 13, no. 14, July 2024, p. e7402. EBSCOhost, https://doi.org/10.1002/cam4.7402.

APA

De Novellis, D., Fontana, R., Serio, B., Vaccaro, E., Guariglia, R., Morini, D., Rizzo, M., Giudice, V., & Selleri, C. (2024). Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab-based regimens. Cancer Medicine, 13(14), e7402. https://doi.org/10.1002/cam4.7402

Chicago

De Novellis, Danilo, Raffaele Fontana, Bianca Serio, Emilia Vaccaro, Roberto Guariglia, Denise Morini, Michela Rizzo, Valentina Giudice, and Carmine Selleri. 2024. “Cytomegalovirus Reactivation Is Frequent in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens.” Cancer Medicine 13 (14): e7402. doi:10.1002/cam4.7402.